One Biotech Stock With Jaw-Dropping Potential

Breakthrough Acoustic Shockwave Revealed   The NASDAQ is full of hidden gems if you know what to look for and, in this edition, we have a very unique opportunity for our subscribers! A med device company that has a proprietary acoustic shockwave device that is targeting a $10 billion aesthetics market. On March 21st, 2020, they will be releasing to the investing public their pivotal cellulite trial data, which was started after they completed a proof-of-concept cellulite trial that resulted in a 20-47% improvement in patient's cellulite severity score! With this news pending, here are a few highlights about the company: They've spent more than $30 million dollars over the past 5 years developing their breakthrough acoustic shockwave device that is targeting tattoo removal, cellulite reduction and keloid/hypertrophic scars Their executive and science advisory teams, as well as their board of directors, are comprised of aesthetic and medical device experts, including senior management from the makers of CoolSculpting (the leading non-surgical fat reduction technology that was acquired by Allergan for over $56 per share, for a total purchase price of $2.4B). They were recently added to the Russell 2000 and 3000 indexes They recently received FDA 510(k) clearance for their Generation 1 device Secured 8 patent families (with 101 patents issued or pending) Completed their IPO at $5 per share and has since reached a high of $29 per share Click this link to [WATCH] a video about this company and to learn about their pending news.   This is a paid message provided to our subscribers. Although we have sent you this email, we do not endorse this product or featured company nor is it responsible for it's content. We make no guarantee or warranty about what is mentioned above.

This is a paid communication provided to customers/subscribers to DailyMarketAlerts. Although we have sent you this email, DailyMarketAlerts does NOT specifically endorse this product nor is it responsible for the content of this communication. Furthermore, we make no guarantee or warranty about what is communicated above.


DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that DailyMarketAlerts is being paid on a cost-per-click basis which may exceed a fee of $1,000.00 in cash, from a third party as compensation for the distribution of this communication. DailyMarketAlerts has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this communication, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely upon. Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.